BACKGROUND
 Nausea and vomiting is one of the most problematic symptoms for patients undergoing chemotherapy.  Aprepitant, a neurokinin-1 receptor antagonist, has been shown to be effective for controlling chemotherapy induced nausea vomiting (CINV).  Aprepitant in combination with a 5-HT3 antagonists and dexamethasone for patients taking multiday chemotherapy has be shown to be effective and safe in studies. o However, it has not been studied in patients receiving multiday chemotherapy for hematologic malignancies. o There was a significant difference between the percentages of patients without vomiting in the aprepitant group compared to the control group. (88% versus 58%, p =0.002) o There was not a significant difference between the percentage of patients without nausea between the groups (31% versus 18%, p = 0.180)  Authors Conclusion: The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies.
STRENTGHS  Baseline characteristics' of the treatment groups were similar  Appropriate doses of the drugs were administered in both study groups  Researchers accurately explained their limitations or weakness in the discussion section LIMITATIONS  Retrospective study design  Study dependent upon accuracy and completeness of existing electronic medical records  No data provided on rescue medication provided  Possible pharmacokinetic s changes of chemotherapy agents due to the addition of aprepitant was not evaluated  Researchers made a generalized statement that the addition of aprepitant has a better antiemetic effect then the control group when in fact it depended on the specific chemotherapy regimen that the patient was given CONCLUSION  Results showed that the addition of aprepitant to granisetron to specific chemotherapy regimens in hematologic malignancies improves antiemetic effect without causing adverse drug events.  Future Research:
o An experimental design study should be conducted to determine true efficacy and safety of aprepitant.
